Products Categories

    Selleck China

    Country: Country China (Mainland)

    Business Type: Trading Company

    qq

  • Ms.Olivia
    Tel: 400-668-6834

  • Mobile:
  • Tel:400-668-6834
  • Fax:
  • Province/state:Shanghai
  • City:Shanghai
  • Street:Building 3, No. 88 Chenhui Road, Kingdee Software Park, Pudong New District, Shanghai, China
  • MaxCard:
Home > Products >  Niraparib (MK-4827)

Niraparib (MK-4827) CAS NO.1038915-60-4

  • Min.Order: 0 Metric Ton
  • Payment Terms:
  • Product Details

Keywords

  • Niraparib
  • MK-4827
  • 1038915-60-4

Quick Details

  • ProName: Niraparib (MK-4827)
  • CasNo: 1038915-60-4
  • Molecular Formula: C19H20N4O
  • ProductionCapacity: Metric Ton/Day
  • Purity: >97%
  • LimitNum: 0 Metric Ton

Superiority

Biological Activity

Description Niraparib (MK-4827) is a selective inhibitor of PARP1/2 with IC50 of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. Niraparib can form PARP–DNA complexes resulting in DNA damage, apoptosis, and cell death. Phase 3.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.1 nM 3.8 nM
In vitro

In a whole cell assay, MK-4827 inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. It was demonstrated to be a potent and selective PARP-1 and PARP-2 inhibitor with IC50=3.8 and 2.1 nM, respectively. Furthermore, it displayed at least a 100-fold selectivity over PARP-3, V-PARP, and tankyrase-1, with IC50 = 1300, 330, and 570 nM, respectively. As well as inhibiting the growth of HeLa cell lacking BRCA-1 because of silencing by RNA interference, MK-4827 is able to inhibit the proliferation of cancer cell lines carrying natural BRCA-1 or BRCA-2 mutations. In MDA-MB-436 human mammary gland adenocarcinoma cells carrying BRCA-1 mutations, MK-4827 displayed CC50 = 18 nM, while in CAPAN-1 human pancreatic adenocarcinoma cells, which are BRCA-2 mutant, MK-4827 displayed CC50 = 90 nM. In contrast, normal human prostate and mammary epithelial cells are resistant to MK-4827, displaying antiproliferative effects in the micromolar range, thereby demonstrating the very high selective cytotoxicity from these PARP inhibitors in BRCA-1 and -2 mutant cancer cells compared to surrounding tissue[2].

Cell Data
 
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa cells Function assay       Inhibition of PARP in hydrogen peroxide-induced human HeLa cells assessed as inhibition DNA-damage-induced PARylation, EC50=0.004 μM 19873981
A549 cells Cytotoxicity assay   5-7 days   Cytotoxicity against human A549 cells transfected with BRCA2 shRNA assessed as inhibition of cell proliferation after 5 to 7 days by CellTiter-Blue assay, CC50=0.011 μM 25761096
MDA-MB-436 cells Proliferation assay   6 days   Antiproliferative activity against human MDA-MB-436 cells expressing BRCA1 5396 + 1G>A mutant after 6 days by cell titer-blue assay, CC50=18 nM 19873981

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot 29158830
Immunofluorescence 27614696
In vivo MK-4827, a novel, orally bioavailable, PARP-1 and PARP-2 inhibitor, strongly enhanced the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant[1]. It was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer[2].

 

Details

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog